Skip to content

A multicenter randomized controlled intervention study on bilateral adrenal artery ablation for the treatment of idiopathic aldosteronism

A multicenter randomized controlled intervention study on bilateral adrenal artery ablation for the treatment of idiopathic aldosteronism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092478
Enrollment
Unknown
Registered
2024-11-18
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Bilateral adrenal artery ablation + spironolactone group:Bilateral adrenal artery ablation + spironolactone

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Hypertensive patients aged 18-70 years; 2. The initial screening showed an aldosterone/renin ratio (ARR)>3.7, baseline aldosterone level>10ng/dl, aldosterone level>6ng/dl after saline stress test, or a 30% decrease in aldosterone after captopril inhibition test, which is consistent with the diagnosis of primary aldosterone; 3. Patients who have not received treatment or are currently receiving antihypertensive medication (medication treatment for blood pressure<180/110mmHg); 4.Adrenal vein blood sampling suggested idiopathic aldosteronism; 5.Voluntarily participate in the experiment and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1. Room blood pressure>180/110mmHg; 2. Severe liver dysfunction (Child Pugh rating of C) or renal dysfunction (eGFR<30mL/min/1.73m ^ 2); Acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, and cerebrovascular accident occurred within 3.6 months; NYHA grade II-IV heart failure; 4. Blood potassium levels are below 2.5mmol/L or above 5.5mmol/L; 5. Pregnancy or planning to conceive within one year; 6. Suffering from neurological and mental illnesses; 7. Combination of malignant tumors; 8. The researcher believes that any other reasons that may affect the efficacy and/or safety evaluation of this study and are not suitable for participation in this clinical trial (including but not limited to the researcher's judgment that the subjects have poor compliance, or reside far away and cannot be followed up on schedule);

Design outcomes

Primary

MeasureTime frame
24 hours ambulatory blood pressure;

Secondary

MeasureTime frame
office blood pressure;Plasma aldosterone;24-hour urinary aldosterone;plasma rennin;Serum potassium;

Countries

China

Contacts

Public ContactZhu Zhiming

Army Medical Center of PLA

hbpcms@sina.com+86 23 68757849

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026